Analysis of the Papillomavirus E2 and Bromodomain Protein Brd4 Interaction Using Bimolecular Fluorescence Complementation

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Helfer, Christine M ^a   Wang, Ranran ^a   You, Jianxin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BROMODOMAIN CONTAINING PROTEIN 4; E2 PROTEIN; JQ1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; BINDING SITE; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HOST PATHOGEN INTERACTION; HUMAN PAPILLOMAVIRUS TYPE 16; INTERPHASE; MITOSIS; NONHUMAN; PAPILLOMA VIRUS; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; VIRUS EXAMINATION; VIRUS GENOME; VIRUS MORPHOGENESIS; VIRUS STRAIN;

BLOTTING, WESTERN; CELL LINE; DNA-BINDING PROTEINS; FLUORESCENCE; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 84886420722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077994     Document Type: Article

References (51)

1. zur Hausen H, (2009) Papillomaviruses in the causation of human cancers- a brief historical account. Virology 384: 260-265. doi:10.1016/j.virol.2008.11.046. PubMed: 19135222.
2. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527. doi:10.1056/NEJMoa021641. PubMed: 12571259.
3. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632. doi:10.1002/ijc.22527. PubMed: 17405118.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19. doi:10.1002/(SICI)1096-9896(199909)189:1. PubMed: 10451482.
5. Doorbar J, (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110: 525-541. doi:10.1042/CS20050369. PubMed: 16597322.
6. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer. Prev Res (Phila) 2: 868-878. doi:10.1158/1940-6207.CAPR-09-0031.
7. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314. doi:10.1016/S0140-6736(09)61248-4. PubMed: 19586656.
8. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341: c3493. doi:10.1136/bmj.c3493. PubMed: 20647284.
9. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, et al. (2009) A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15: 361-367. doi:10.1158/1078-0432.CCR-08-1725. PubMed: 19118066.
10. Ault KA, (2007) Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 107: S31-S33. doi:10.1016/j.ygyno.2007.08.059. PubMed: 18499916.
11. Stanley MA, (2012) Genital human papillomavirus infections: current and prospective therapies. J Gen Virol 93: 681-691. doi:10.1099/vir.0.039677-0. PubMed: 22323530.
12. White PW, Faucher AM, Massariol MJ, Welchner E, Rancourt J, et al. (2005) Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother 49: 4834-4842. doi:10.1128/AAC.49.12.4834-4842.2005. PubMed: 16304143.
13. White PW, Faucher AM, Goudreau N, (2011) Small molecule inhibitors of the human papillomavirus E1-E2 interaction. Curr Top Microbiol Immunol 348: 61-88. PubMed: 20676971.
14. McBride AA, Romanczuk H, Howley PM, (1991) The papillomavirus E2 regulatory proteins. J Biol Chem 266: 18411-18414. PubMed: 1655748.
15. Spalholz BA, Yang YC, Howley PM, (1985) Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product. Cell 42: 183-191. doi:10.1016/S0092-8674(85)80114-8. PubMed: 2990724.
16. Kim J, Lee D, Gwan Hwang S, Hwang ES, Choe J, (2003) BRCA1 associates with human papillomavirus type 18 E2 and stimulates E2-dependent transcription. Biochem Biophys Res Commun 305: 1008-1016. doi:10.1016/S0006-291X(03)00880-5. PubMed: 12767931.
17. Kumar RA, Naidu SR, Wang X, Imbalzano AN, Androphy EJ, (2007) Interaction of papillomavirus E2 protein with the Brm chromatin remodeling complex leads to enhanced transcriptional activation. J Virol 81: 2213-2220. doi:10.1128/JVI.01746-06. PubMed: 17151122.
18. Lee D, Hwang SG, Kim J, Choe J, (2002) Functional interaction between p/CAF and human papillomavirus E2 protein. J Biol Chem 277: 6483-6489. doi:10.1074/jbc.M105085200. PubMed: 11744716.
19. Lee D, Lee B, Kim J, Kim DW, Choe J, (2000) cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J Biol Chem 275: 7045-7051. doi:10.1074/jbc.275.10.7045. PubMed: 10702269.
20. McPhillips MG, Oliveira JG, Spindler JE, Mitra R, McBride AA, (2006) Brd4 is required for e2-mediated transcriptional activation but not genome partitioning of all papillomaviruses. J Virol 80: 9530-9543. doi:10.1128/JVI.01105-06. PubMed: 16973557.
21. Schweiger MR, You J, Howley PM, (2006) Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. J Virol 80: 4276-4285. doi:10.1128/JVI.80.9.4276-4285.2006. PubMed: 16611886.
22. Schweiger MR, Ottinger M, You J, Howley PM, (2007) Brd4-independent transcriptional repression function of the papillomavirus e2 proteins. J Virol 81: 9612-9622. doi:10.1128/JVI.00447-07. PubMed: 17626100.
23. Smith JA, White EA, Sowa ME, Powell ML, Ottinger M, et al. (2010) Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc Natl Acad Sci U S A 107: 3752-3757. doi:10.1073/pnas.0914818107. PubMed: 20133580.
24. Tan SH, Leong LE, Walker PA, Bernard HU, (1994) The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J Virol 68: 6411-6420. PubMed: 8083979.
25. Wu SY, Lee AY, Hou SY, Kemper JK, Erdjument-Bromage H, et al. (2006) Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev 20: 2383-2396. doi:10.1101/gad.1448206. PubMed: 16921027.
26. Skiadopoulos MH, McBride AA, (1998) Bovine papillomavirus type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin. J Virol 72: 2079-2088. PubMed: 9499063.
27. Bastien N, McBride AA, (2000) Interaction of the papillomavirus E2 protein with mitotic chromosomes. Virology 270: 124-134. doi:10.1006/viro.2000.0265. PubMed: 10772985.
28. Piirsoo M, Ustav E, Mandel T, Stenlund A, Ustav M, (1996) Cis and trans requirements for stable episomal maintenance of the BPV-1 replicator. EMBO J 15: 1-11. PubMed: 8598191.
29. Ilves I, Kivi S, Ustav M, (1999) Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which Is mediated by the viral E2 protein and its binding sites. J Virol 73: 4404-4412. PubMed: 10196338.
30. Lehman CW, Botchan MR, (1998) Segregation of viral plasmids depends on tethering to chromosomes and is regulated by phosphorylation. Proc Natl Acad Sci U S A 95: 4338-4343. doi:10.1073/pnas.95.8.4338. PubMed: 9539738.
31. You J, Croyle JL, Nishimura A, Ozato K, Howley PM, (2004) Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117: 349-360. doi:10.1016/S0092-8674(04)00402-7. PubMed: 15109495.
32. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K, (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A 100: 8758-8763. doi:10.1073/pnas.1433065100. PubMed: 12840145.
33. Baxter MK, McPhillips MG, Ozato K, McBride AA, (2005) The mitotic chromosome binding activity of the papillomavirus E2 protein correlates with interaction with the cellular chromosomal protein, Brd4. J Virol 79: 4806-4818. doi:10.1128/JVI.79.8.4806-4818.2005. PubMed: 15795266.
34. McPhillips MG, Ozato K, McBride AA, (2005) Interaction of bovine papillomavirus E2 protein with Brd4 stabilizes its association with chromatin. J Virol 79: 8920-8932. doi:10.1128/JVI.79.14.8920-8932.2005. PubMed: 15994786.
35. Brannon AR, Maresca JA, Boeke JD, Basrai MA, McBride AA, (2005) Reconstitution of papillomavirus E2-mediated plasmid maintenance in Saccharomyces cerevisiae by the Brd4 bromodomain protein. Proc Natl Acad Sci U S A 102: 2998-3003. doi:10.1073/pnas.0407818102. PubMed: 15710895.
36. Abbate EA, Voitenleitner C, Botchan MR, (2006) Structure of the papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates HPV chromosomal association. Mol Cell 24: 877-889. doi:10.1016/j.molcel.2006.11.002. PubMed: 17189190.
37. Ilves I, Mäemets K, Silla T, Janikson K, Ustav M, (2006) Brd4 is involved in multiple processes of the bovine papillomavirus type 1 life cycle. J Virol 80: 3660-3665. doi:10.1128/JVI.80.7.3660-3665.2006. PubMed: 16537635.
38. Gagnon D, Joubert S, Sénéchal H, Fradet-Turcotte A, Torre S, et al. (2009) Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4. J Virol 83: 4127-4139. doi:10.1128/JVI.02468-08. PubMed: 19211738.
39. Wang X, Helfer CM, Pancholi N, Bradner JE, You J, (2013) Recruitment of Brd4 to the human papillomavirus type 16 DNA replication complex is essential for replication of viral DNA. J Virol 87: 3871-3884. doi:10.1128/JVI.03068-12. PubMed: 23365439.
40. Yan J, Li Q, Lievens S, Tavernier J, You J, (2010) Abrogation of the Brd4-positive transcription elongation factor B complex by papillomavirus E2 protein contributes to viral oncogene repression. J Virol 84: 76-87. doi:10.1128/JVI.01647-09. PubMed: 19846528.
41. Wang R, Li Q, Helfer CM, Jiao J, You J, (2012) The bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J Biol Chem.
42. Flores ER, Allen-Hoffmann BL, Lee D, Sattler CA, Lambert PF, (1999) Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 262: 344-354. doi:10.1006/viro.1999.9868. PubMed: 10502513.
43. Yan J, Diaz J, Jiao J, Wang R, You J, (2011) Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma. J Biol Chem 286: 27663-27675. doi:10.1074/jbc.M111.246975. PubMed: 21652721.
44. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. (2010) Selective inhibition of BET bromodomains. Nature 468: 1067-1073. doi:10.1038/nature09504. PubMed: 20871596.
45. Kerppola TK, (2006) Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nat Protoc 1: 1278-1286. doi:10.1038/nprot.2006.201. PubMed: 17406412.
46. Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM, (2013) Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell 49: 843-857. doi:10.1016/j.molcel.2012.12.006. PubMed: 23317504.
47. Kodama Y, Hu CD, (2010) An improved bimolecular fluorescence complementation assay with a high signal-to-noise ratio. BioTechniques 49: 793-805. doi:10.2144/000113519. PubMed: 21091444.
48. Nakagawa C, Inahata K, Nishimura S, Sugimoto K, (2011) Improvement of a Venus-based bimolecular fluorescence complementation assay to visualize bFos-bJun interaction in living cells. Biosci Biotechnol Biochem 75: 1399-1401. doi:10.1271/bbb.110189. PubMed: 21737916.
49. Dostatni N, Thierry F, Yaniv M, (1988) A dimer of BPV-1 E2 containing a protease resistant core interacts with its DNA target. EMBO J 7: 3807-3816. PubMed: 2850174.
50. Cardenas-Mora J, Spindler JE, Jang MK, McBride AA, (2008) Dimerization of the papillomavirus E2 protein is required for efficient mitotic chromosome association and Brd4 binding. J Virol 82: 7298-7305. doi:10.1128/JVI.00772-08. PubMed: 18495759.
51. Sénéchal H, Poirier GG, Coulombe B, Laimins LA, Archambault J, (2007) Amino acid substitutions that specifically impair the transcriptional activity of papillomavirus E2 affect binding to the long isoform of Brd4. Virology 358: 10-17. doi:10.1016/j.virol.2006.08.035. PubMed: 17023018.